A report by Transparency Research, titled, “Angiosarcomas Treatment Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2016 – 2024,” suggests a rise in angiosarcomas cancer cases, thus leading towards a higher number of treatments carried out globally.
Get Report Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=14942
The cause of angiosarcomas cancer is unknown in most cases. However, lymphedema which is the swelling of an area of the body due to collection of fluid, is proven to cause this disease, thus being a significant driver for this market. Exposure to intense radiations, and continued subjection to carcinogens such as arsenic, vinyl chloride, and thorium dioxide, are some of the prominent fueling factors for the global angiosarcomas treatment market. The high fatality rate of this cancer demands a prompt treatment. Such a need has led towards speedy development of treatment options such as surgery, chemotherapy, and radiation therapy. This has resulted in extensive growth in the global angiosarcomas treatment market.
The global angiosarcomas market is segmented on the basis of tumor instigation and region. Under tumor instigation, the market consists of two segments – hemagiosarcoma and lymphangiosarcome. The former one indicates cancer origins in the blood vessels, whereas the latter originates in the lymph vessels. Region-wise, the angiosarcomas treatment market is spread across North America, Europe, the Middle East and Africa, Asia Pacific, and Europe. Among these, North America showcases maximum expansion of the market’s scope. This is mainly due to several factors such as hereditary passage of disease and large number of radiation exposure cases.
Owing to the sensitive nature of the cancer along with nascent developmental stages, the vendor landscape is highly consolidated. This is mainly because of few companies choosing to extend their knowledge towards developing improved treatments and potential solutions. Amgen, Inc., Pfizer, Inc., Janssen Products, Genentech, Inc., LP, Sanofi S.A., and Bayer Healthcare are some the major players operating in the global angiosarcomas market.